Paclitaxel (PTX) is a first‐line chemotherapeutic drug for non‐small cell lung cancer (NSCLC) but it can induce indoleamine 2,3‐dioxygenase (IDO) activation, which severely lowers down its immuno‐chemotherapeutic effect. Here, IDO2 is linked to lung cancer.